8Donough RP, Rovers JP, Currie JD, et al. Obstacles to the implemen- tation of pharmaceutical care in the community setting [ J ]. J Am Pharm Assoc,1998,38( 1 ) :87.
9卫生部国家中医药管理局.医疗机构药事管理暂行规定[S].2002.
10Hepler CD. The third waveinpharmacentical education: the clinical movement [J]. AmJPharmEduc, 1987, 51 (4): 369.
1Stang P E,Ryan P B,Racoosin J A,et al. Advancing the science for active surveillance:rationale and design for the Observational Medical Outcomes Partnershop [J]. Annals o f Internal Medicine,2010,153:600-606.
2FDA.FDA's Sentinel Initiative-Background. http://www.fda.gov/Safety/ FDAs S entinellnitiative/ucm 149340.htm,2010-01 - 19/2014-12-23.
3Yu-Lin Huang,Jinhee Moon,Jodi B Segal.A Comparison of Active Adverse Event Surveillance Systems Worldwide[J].DrugSaf,2014;37(8):581-596.
4Jose Luis Oliveira,Pedro Lopes,Tiago Nunes,et al. The EU-ADR Web Platform:delivering advanced pharmacovigilance tools[J]. Pharmacoepidemiology and drug safety,2013;22(5):459-467.
5EMA.Objectives of PROTECT.http://www.imi-protect.eu/objectives. shtml,/2014-12-23.
